In this issue:
Diagnostic radiation risks APBI outcomes
Brain metastases in TNBC
Physical activity and recurrence risk
TDM-1 immunoconjugate in HER2+ patients
Predicting recurrence-free progression
Comparing trastuzumab administration routes
Update: mTOR inhibitors
Please login below to download this issue (PDF)